Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Khadge S, Sharp JG, McGuire TR, Thiele GM, Black P, DiRusso C, Cook L, Klassen LW, Talmadge JE.

Int Immunopharmacol. 2018 Nov 14;65:580-592. doi: 10.1016/j.intimp.2018.10.026. [Epub ahead of print] Review.

PMID:
30447537
2.

Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.

Khadge S, Thiele GM, Sharp JG, McGuire TR, Klassen LW, Black PN, DiRusso CC, Cook L, Talmadge JE.

Clin Exp Metastasis. 2018 Oct 16. doi: 10.1007/s10585-018-9941-7. [Epub ahead of print]

PMID:
30327985
3.

Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions.

Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH, Batra SK, Datta K.

Cancer Res. 2018 Oct 1;78(19):5600-5617. doi: 10.1158/0008-5472.CAN-18-0562. Epub 2018 Aug 15.

PMID:
30111533
4.

Long-Chain Omega-3 Polyunsaturated Fatty Acids Modulate Mammary Gland Composition and Inflammation.

Khadge S, Thiele GM, Sharp JG, McGuire TR, Klassen LW, Black PN, DiRusso CC, Talmadge JE.

J Mammary Gland Biol Neoplasia. 2018 Jun;23(1-2):43-58. doi: 10.1007/s10911-018-9391-5. Epub 2018 Mar 25.

PMID:
29574638
5.

Lipid Inflammatory Mediators in Cancer Progression and Therapy.

Khadge S, Sharp JG, McGuire TR, Thiele GM, Talmadge JE.

Adv Exp Med Biol. 2017;1036:145-156. doi: 10.1007/978-3-319-67577-0_10. Review.

PMID:
29275470
6.

Tumor Immuno-Environment in Cancer Progression and Therapy.

Kalinski P, Talmadge JE.

Adv Exp Med Biol. 2017;1036:1-18. doi: 10.1007/978-3-319-67577-0_1.

PMID:
29275461
7.

Role of the EHD Family of Endocytic Recycling Regulators for TCR Recycling and T Cell Function.

Iseka FM, Goetz BT, Mushtaq I, An W, Cypher LR, Bielecki TA, Tom EC, Arya P, Bhattacharyya S, Storck MD, Semerad CL, Talmadge JE, Mosley RL, Band V, Band H.

J Immunol. 2018 Jan 15;200(2):483-499. doi: 10.4049/jimmunol.1601793. Epub 2017 Dec 6.

PMID:
29212907
8.

Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy.

Roy S, Bag AK, Singh RK, Talmadge JE, Batra SK, Datta K.

Front Immunol. 2017 Oct 10;8:1228. doi: 10.3389/fimmu.2017.01228. eCollection 2017. Review.

9.

Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.

Talmadge JE.

Clin Cancer Res. 2016 Jul 15;22(14):3419-21. doi: 10.1158/1078-0432.CCR-16-0246. Epub 2016 Mar 23.

10.

Introduction: Natural product-based drug discovery in Immunopharmacology.

Abe F, Marceau F, Talmadge JE.

Int Immunopharmacol. 2016 Aug;37:1-2. doi: 10.1016/j.intimp.2016.01.017. Epub 2016 Mar 15. No abstract available.

PMID:
26987504
11.

Natural product derived immune-regulatory agents.

Talmadge JE.

Int Immunopharmacol. 2016 Aug;37:5-15. doi: 10.1016/j.intimp.2016.02.025. Epub 2016 Mar 8. Review.

PMID:
26968760
12.

Editorial: Improving the data reproducibility and general interest of natural product submissions.

Marceau F, Abe F, Talmadge JE.

Int Immunopharmacol. 2016 Aug;37:3-4. doi: 10.1016/j.intimp.2015.11.038. Epub 2015 Dec 8. No abstract available.

PMID:
26674722
13.

Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.

An W, Nadeau SA, Mohapatra BC, Feng D, Zutshi N, Storck MD, Arya P, Talmadge JE, Meza JL, Band V, Band H.

Oncotarget. 2015 Apr 30;6(12):10498-509.

14.

Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Wang J, McGuire TR, Britton HC, Schwarz JK, Loberiza FR Jr, Meza JL, Talmadge JE.

Clin Exp Metastasis. 2015 Feb;32(2):111-24. doi: 10.1007/s10585-015-9696-3. Epub 2015 Jan 25.

PMID:
25617965
15.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

16.

Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.

Younos IH, Abe F, Talmadge JE.

Leuk Lymphoma. 2015;56(8):2251-63. doi: 10.3109/10428194.2014.987141. Epub 2015 Jan 21. Review.

PMID:
25407654
17.

Dendritic cells transfected with adenoviral vectors as vaccines.

Senesac J, Gabrilovich D, Pirruccello S, Talmadge JE.

Methods Mol Biol. 2014;1139:97-118. doi: 10.1007/978-1-4939-0345-0_10.

PMID:
24619674
18.

History of myeloid-derived suppressor cells.

Talmadge JE, Gabrilovich DI.

Nat Rev Cancer. 2013 Oct;13(10):739-52. doi: 10.1038/nrc3581. Review.

19.

Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking.

Younos IH, Dafferner AJ, Gulen D, Britton HC, Talmadge JE.

Int Immunopharmacol. 2012 Jul;13(3):245-56. doi: 10.1016/j.intimp.2012.05.002. Epub 2012 May 17.

PMID:
22609473
20.

Development and application of site-specific proteomic approach for study protein S-nitrosylation.

Liu M, Talmadge JE, Ding SJ.

Amino Acids. 2012 May;42(5):1541-51. doi: 10.1007/s00726-012-1279-x. Epub 2012 Apr 5. Review.

PMID:
22476348
21.

Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical use.

Gülen D, Maas S, Julius H, Warkentin P, Britton H, Younos I, Senesac J, Pirruccello SM, Talmadge JE.

Int Immunopharmacol. 2012 May;13(1):61-8. doi: 10.1016/j.intimp.2012.03.009. Epub 2012 Mar 27.

PMID:
22465385
22.

Bioluminescence in drug development for cancer: shedding light on therapeutic efficacy.

Talmadge JE.

Cancer Biol Ther. 2011 May 1;11(9):846-8. Epub 2011 May 1. No abstract available.

PMID:
21436622
23.

Natural products. Preface.

Abe F, Cao X, Li XK, Talmadge JE.

Int Immunopharmacol. 2011 Mar;11(3):293-4. doi: 10.1016/j.intimp.2010.11.030. Epub 2010 Dec 13. No abstract available.

PMID:
21156220
24.

Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.

Talmadge JE.

Semin Cancer Biol. 2011 Apr;21(2):131-8. doi: 10.1016/j.semcancer.2010.12.002. Epub 2010 Dec 9. Review.

PMID:
21145968
25.

AACR centennial series: the biology of cancer metastasis: historical perspective.

Talmadge JE, Fidler IJ.

Cancer Res. 2010 Jul 15;70(14):5649-69. doi: 10.1158/0008-5472.CAN-10-1040. Epub 2010 Jul 7. Review.

26.

Models of metastasis in drug discovery.

Talmadge JE.

Methods Mol Biol. 2010;602:215-33. doi: 10.1007/978-1-60761-058-8_13.

PMID:
20012401
27.

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.

Abe F, Younos I, Westphal S, Samson H, Scholar E, Dafferner A, Hoke TA, Talmadge JE.

Int Immunopharmacol. 2010 Jan;10(1):140-5. doi: 10.1016/j.intimp.2009.09.023. Epub 2009 Oct 12.

PMID:
19833232
28.

Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.

Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE.

Cancer Immunol Immunother. 2010 Jan;59(1):47-62. doi: 10.1007/s00262-009-0719-2. Epub 2009 May 18.

PMID:
19449184
29.

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J, Talmadge JE.

Int Immunopharmacol. 2009 Jul;9(7-8):937-48. doi: 10.1016/j.intimp.2009.03.021. Epub 2009 Apr 9.

PMID:
19362167
30.

Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviral-triggered anaphylactoid-type reactions.

Pande K, Ueda R, Machemer T, Sathe M, Tsai V, Brin E, Delano MJ, Van Rooijen N, McClanahan TK, Talmadge JE, Moldawer LL, Phillips JH, LaFace DM.

Mol Ther. 2009 Mar;17(3):508-15. doi: 10.1038/mt.2008.280. Epub 2009 Jan 6.

31.

Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy.

Talmadge JE, Cowan KH, Reed EC.

Immunotherapy. 2009 Jan;1(1):5-9. doi: 10.2217/1750743X.1.1.5. Review. No abstract available.

32.

Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.

Gulen D, Abe F, Maas S, Reed E, Cowan K, Pirruccello S, Wisecarver J, Warkentin P, Northam M, Turken O, Coskun U, Senesac J, Talmadge JE.

Int Immunopharmacol. 2008 Dec 20;8(13-14):1728-36. doi: 10.1016/j.intimp.2008.08.010. Epub 2008 Sep 13.

PMID:
18793758
33.

Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule.

Tuli A, Sharma M, McIlhaney MM, Talmadge JE, Naslavsky N, Caplan S, Solheim JC.

J Immunol. 2008 Aug 1;181(3):1978-87.

34.

Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.

Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N, Matsushima K.

Blood. 2008 Jun 15;111(12):5457-66. doi: 10.1182/blood-2008-01-136895. Epub 2008 Mar 28.

35.

Follistatin as an inhibitor of experimental metastasis.

Talmadge JE.

Clin Cancer Res. 2008 Feb 1;14(3):624-6. doi: 10.1158/1078-0432.CCR-07-2216. No abstract available.

36.

Clonal selection of metastasis within the life history of a tumor.

Talmadge JE.

Cancer Res. 2007 Dec 15;67(24):11471-5. Review. No abstract available.

37.

Lymphocyte subset recovery following allogeneic bone marrow transplantation: CD4(+)-cell count and transplant-related mortality.

Talmadge JE.

Bone Marrow Transplant. 2008 Jan;41(1):19-21. Epub 2007 Oct 15. No abstract available.

PMID:
17934531
39.

Inflammatory cell infiltration of tumors: Jekyll or Hyde.

Talmadge JE, Donkor M, Scholar E.

Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400. Review.

PMID:
17717638
40.

CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors.

Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC.

Cancer Biol Ther. 2007 Aug;6(8):1206-10. Epub 2007 May 7.

PMID:
17617742
41.

Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma.

Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC.

Cancer Biother Radiopharm. 2007 Apr;22(2):235-8.

PMID:
17600470
42.

Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Singh RK, Varney ML, Leutzinger C, Vose JM, Bierman PJ, Buyukberber S, Ino K, Loh K, Nichols C, Inwards D, Rifkin R, Talmadge JE.

Int Immunopharmacol. 2007 Aug;7(8):1033-43. Epub 2007 Apr 20.

43.

Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Talmadge JE, Singh RK, Fidler IJ, Raz A.

Am J Pathol. 2007 Mar;170(3):793-804. Review.

45.

CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity.

Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC.

Int J Oncol. 2007 Mar;30(3):631-9.

PMID:
17273764
46.

Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.

Solheim JC, Reber AJ, Ashour AE, Robinson S, Futakuchi M, Kurz SG, Hood K, Fields RR, Shafer LR, Cornell D, Sutjipto S, Zurawski S, LaFace DM, Singh RK, Talmadge JE.

Cancer Gene Ther. 2007 Apr;14(4):364-71. Epub 2007 Jan 19.

PMID:
17235356
47.

CCL21-induced immune cell infiltration.

Ashour AE, Turnquist HR, Singh RK, Talmadge JE, Solheim JC.

Int Immunopharmacol. 2007 Feb;7(2):272-6. Epub 2006 Nov 13.

PMID:
17178395
48.

Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.

Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M, Toth B.

Int Immunopharmacol. 2007 Feb;7(2):140-51. Epub 2006 Oct 24.

PMID:
17178380
49.

New standards for manuscripts on natural products.

Talmadge JE, Hugli TE, Fuminori A.

Int Immunopharmacol. 2006 Aug;6(8):1223. Epub 2006 Apr 19. No abstract available.

PMID:
16782533
50.

Editorial.

Talmadge JE, Hugli TE, Fuminori A.

Int Immunopharmacol. 2006 Jul;6(7):1039. Epub 2006 Apr 19. No abstract available.

PMID:
16714206

Supplemental Content

Loading ...
Support Center